Menu

Category: Pharma Industry

Two High Profile Opioid Makers Among Companies Announcing Refunds to 340B Providers But Refunds for Mallinckrodt’s Top-Selling Drug Remain Elusive

In Judicial, Pharma Industry176 Views Ted Slafsky
Refunds for Mallinckrodt’s top-selling drug is noticeably absent from recent posting.
For the fourth time since 2020, Purdue Pharma has announced refunds to 340B covered entities for overcharges. Purdue, which pled guilty in November in federal court to fraud and kickback charges related to its role in fueling the national opioid-abuse …
Read More »

Boehringer Ingelheim Will Stop Shipping 340B Drugs to Hospitals’ Contract Pharmacies on Aug. 1

In Breaking, Pharma Industry2867 Views Tom Mirga
Hospitals call Boehringer Ingelheim’s contract pharmacy plans “appalling” while company calls for “substantial reform” of the 340B program.

Drug manufacturer Boehringer Ingelheim (BI) announced yesterday that it will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.

Community health centers, HIV/AIDS clinics, and other federal grantee covered entities are exempt from BI’s new policy. It applies

…
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 6

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports345 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
As we described in Parts 2 and 3 of this series, in 2018, an ex-Celgene vice president responsible for the company’s 340B program compliance alleged in a whistleblower lawsuit that Celgene’s reason for limiting Revlimid, Pomalyst, and Thalomid’s distribution is …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 5

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports368 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Last September, the Democratic-controlled U.S. House Oversight and Reform Committee released a 45-page report focused on Celgene and Bristol Myers Squibb’s (BMS’s) nearly two dozen price increases on Revlimid from 2005, when Celgene bought the drug, through 2019. It was …
Read More »

More Than a Third of State Lawmakers Accept Pharma Campaign Contributions, Analysis Shows

In Legislative, Pharma Industry, State112 Views Tom Mirga
More than one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution during the past two years, an analysis of campaign finance records by news organization STAT found.
In the last two years, over one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution, news organization STAT reports.

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 4

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports512 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according to numerous health system representatives that 340B Report interviewed. (All current and former health …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports647 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The myeloma drugs Revlimid and Pomalyst are analogues of Thalomid, aka thalidomide—a drug that still haunts those who remember the late 1950s and early 1960s. Marketed mainly in Europe as an over the counter sedative and morning sickness medicine for …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 2

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports893 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or questionable conduct by Celgene with respect to its myeloma drugs and the 340B program. BMS said: “Bristol Myers Squibb …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 1

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports1403 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 1 of 6—Why Can So Few 340B Hospitals Buy and Dispense the Highly Profitable Cancer Drug Revlimid?

Possibly more than a thousand hospitals in the 340B drug discount program can’t buy or dispense Revlimid, a widely-used oral drug to

…
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report